What Curigin does

Curigin is a Seoul-based, private biotechnology company founded in 2016 that develops RNA-based therapeutics using proprietary oligonucleotide and viral delivery platforms. The company operates three core technology assets: a Bi-specific siRNA platform enabling simultaneous gene silencing of two targets, a Viral Capsid Engineering capability for optimized therapeutic delivery, and an Aptamer-siRNA Complex format that combines aptamer targeting with siRNA payloads. The company publicly claims to have developed what it characterizes as the world's shortest dual-target siRNA technology, positioning the platform as a differentiator versus single-target siRNA therapeutics.

The company targets the therapeutics and pharmaceutical industry as its primary customer segment, with stated end-use cases spanning AOC (Antibody-Oligonucleotide Conjugate) therapeutics, targeted cancer therapy, and treatment of genetic diseases. Customer segmentation is described as horizontal, addressing the unmet need for more effective targeted therapeutics with improved specificity and reduced off-target effects. The company is led by CEO Wan Lee and operates with a small team of 11-50 employees from its headquarters in Seongdong-gu, Seoul.

As a pre-commercial R&D-stage biopharmaceutical company, Curigin's business model relies on co-development partnerships rather than direct product sales. The company has executed two strategic co-development alliances: with Aptamer Sciences (announced June 2025) for aptamer-siRNA complex targeted therapeutics, and with April Bio (announced February 2026) for AOC treatment development. Pricing is not publicly disclosed, no revenue figures are available, and the only confirmed capital event is an undisclosed investment by Company K Partners in January 2018. The company maintains a LinkedIn presence and relies on Korean business media coverage as its primary communication channels.

Name

Curigin

Legal name

Curigin Inc.

Website

https://curigin.co.kr

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Seoul-based pre-clinical biotechnology company developing proprietary Bi-specific siRNA and Viral Capsid Engineering platforms for targeted RNA therapeutics. Partners with pharmaceutical companies to co-develop Aptamer-siRNA complexes and AOC therapeutics.

Ownership category

akta.pro rank

Product category

Biopharmaceutical R&D / RNA Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

akta.pro secondary industries

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE)

Keywords

• RNA therapeutics development
• SiRNA drug discovery
• Viral capsid engineering
• Targeted gene therapy
• Oligonucleotide therapeutics

Headquarters

HQ city

Songdong

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Marketing channels2 records

Core offering

Curigin develops proprietary RNA-based therapeutic platforms, primarily a Bi-specific siRNA technology for simultaneous dual-target gene silencing and a Viral Capsid Engineering capability for targeted therapeutic delivery. The company builds pipeline candidates including aptamer-siRNA complexes and antibody-oligonucleotide conjugates (AOC), advancing them through R&D and co-development partnerships with other pharmaceutical firms.

Product overview

Curigin is a biotechnology company developing RNA-based therapeutics using its proprietary bi-specific siRNA technology platform and viral capsid engineering capabilities. The company is building a pipeline of targeted therapeutics including aptamer-siRNA complexes (in partnership with Aptamer Science) and AOC (antibody-oligonucleotide conjugate) treatments (in partnership with April Bio). The core technology consists of dual-targeting siRNA platform for simultaneous gene silencing and viral capsid engineering for therapeutic delivery.

Differentiator

Problem solved

Functional benefit

Products and services

• Bi-specific siRNA Technology Platform A dual-targeting siRNA (small interfering RNA) technology platform that enables simultaneous gene silencing of two targets. The company claims breakthrough capability in developing the world's shortest dual-target siRNA for innovative drug development, intended for pharmaceutical and biotechnology partners developing novel therapeutic modalities.
• Viral Capsid Engineering Platform Engineering technology for viral capsids used for targeted delivery of therapeutic payloads including siRNA. Designed to address delivery challenges in oligonucleotide therapeutics for pharmaceutical and biotechnology partners.
• Aptamer-siRNA Complex Targeted Therapeutics Jointly developed targeted therapeutic combining aptamer and siRNA technologies for precision treatment. Developed in partnership with Aptamer Sciences (압타머사이언스), announced June 2025, intended for pharmaceutical companies developing high-specificity targeted treatment modalities.
• AOC (Antibody-Oligonucleotide Conjugate) Therapeutics Antibody-oligonucleotide conjugate (AOC) treatment development, partnered with April Bio (에이프릴바이오). Collaboration leverages both companies' technologies to advance novel antibody-oligonucleotide conjugate treatments for pharmaceutical development.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• April Bio (에이프릴바이오)coreStrategic or Co-development Partner · 1 February 2026Partnership for AOC (Antibody-Oligonucleotide Conjugate) therapeutics development. Collaboration leverages both companies' technologies to advance novel antibody-oligonucleotide conjugate treatments.
• Aptamer Sciences (압타머사이언스)coreStrategic or Co-development Partner · 1 June 2025Strategic partnership for co-development of Aptamer-siRNA complex targeted therapeutics. The collaboration combines Aptamer Sciences' aptamer technology with Curigin's siRNA platform to develop novel targeted treatment modalities.

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Dicerna Pharmaceuticals: siRNA platform company acquired by Novo Nordisk (2021), with GalXC delivery technology and partnered programs with Roche, Lilly, and others. Comparable as a now-acquired siRNA platform that validates the acquisition thesis around similar assets.
• Avidity Biosciences: Clinical-stage company pioneering antibody-oligonucleotide conjugates (AOCs), the same emerging modality Curigin is pursuing via its April Bio partnership. Directly comparable on AOC modality specifically.

Direct peers

• Stoke Therapeutics: Clinical-stage company developing antisense oligonucleotide medicines (TANGO platform) for genetic diseases. Comparable as a precision oligonucleotide platform company targeting rare diseases with platform-based pipeline expansion.
• Silence Therapeutics: Clinical-stage siRNA company with mRNAi GOLD platform and partnered programs with AstraZeneca and others. Comparable as a similarly positioned siRNA platform company pursuing partnered pipeline economics.
• Alnylam Pharmaceuticals: Global leader in siRNA therapeutics with approved products (Onpattro, Givlaari, etc.) and broad pipeline across hepatic and extra-hepatic targets. Directly comparable as the defining player in the same siRNA modality Curigin is pursuing.
• Arrowhead Pharmaceuticals: Clinical-stage siRNA company with proprietary TRiM delivery platform targeting hepatic and extra-hepatic tissues. Highly comparable as a direct siRNA competitor with broad pipeline and multiple big-pharma partnerships.
• Wave Life Sciences: Clinical-stage nucleic acid therapeutics company with PRISM platform spanning siRNA, antisense, and stereopure oligonucleotides. Comparable as a platform oligonucleotide company developing precision genetic medicines.
• Arbutus Biopharma: Clinical-stage company developing RNAi therapeutics with proprietary GalNAc conjugate delivery technology. Comparable as a focused siRNA platform player with strong delivery chemistry expertise.

Emerging players

• Suzhou Ribo Life Science: China-based clinical-stage siRNA company developing RNAi therapeutics across hepatic and extra-hepatic indications. Comparable as a regionally-focused emerging siRNA platform in an adjacent Asia-Pacific market.
• Bio-Path Holdings: Clinical-stage oligonucleotide therapeutics company with DNAbilize technology for cancer and rare diseases. Comparable as a small-cap emerging oligonucleotide platform pursuing partnered pipeline development.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/curigin-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curigin